Immunity to COVID-19: August update

New studies on COVID-19 immune response are advancing our understanding of this disease in both symptomatic and asymptomatic cases. There is increasing evidence that the differing severity of COVID-19 between individuals is a consequence of a diverse range of immune responses to the virus.
There is some evidence that antibodies can be detected in recovered patients for up to 2–3 months after symptoms. A role for the adaptive cellular immune system, especially T cells, in responding to SARS-CoV…

Read more

COVID-19 Vaccines: July update on research

There are almost 150 coronavirus vaccine candidates under development. Only 19 of these are now being tested in humans. Many types of vaccines are rapidly progressing through clinical trials. Only two vaccine candidates have announced large scale Phase 3 trials, involving several thousands of people. Only one candidate has been approved for restricted human use. Measuring a reduction in COVID-19 levels is an obstacle for Phase 3 clinical trials, as they require a high infection rate among the te…

Read more